enGene Bio - קפיטליזציית שוק ENGN
This daily price chart for enGene Holdings Inc. (ENGN) demonstrates a market capitalization of 0.11. enGene Holdings Inc. (ENGN) focuses on preparing data for its innovative drug EG-70 designed to combat bladder cancer. The business relies on developing gene therapies for mucosal membranes, protecting its innovations with patents. Meanwhile, the development strategy is based on bioethical principles and the ecological disposal of laboratory waste.
פילוחי מדדים מקיפים ואנליטיקה עבור enGene Corp (ENGN)
enGene Holdings Inc. specializes in developing innovative immunotherapy methods to combat oncological diseases. Analyzing the company's market capitalization chart, an investor sees the aggregate value of all shares at the current price. This metric reflects the market valuation of the business and its investment attractiveness. For biopharmaceuticals, this indicator depends directly on the success of clinical trials and patent protection. The price action serves as an indicator of market confidence in the potential of new drugs.